Physician profile
Robert Daniel Soliz
NPI 1619434792
$3,900.84
in general payments reported to CMS, 2019-2025
25 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $886 · 2022: $999 · 2023: $990 · 2024: $552 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,016.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,643.96 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $564.68 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $322.13 | 2021-2023 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $220.31 | 2021-2023 | Mounjaro, Trulicity, Zepbound |
| Abbvie INC. | $205.19 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $158.60 | 2021-2024 | Linzess |
| Astrazeneca Pharmaceuticals LP | $130.12 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $95.47 | 2022-2025 | |
| Astellas Pharma US INC | $71.15 | 2021-2022 | |
| Dexcom, INC. | $70.43 | 2022-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $67.66 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.03 | 2022-2024 | Xifaxan, Trulance |
| Optinose US, INC. | $40.51 | 2022-2023 | |
| Corcept Therapeutics | $33.39 | 2024 | Korlym |
| Merck Sharp & Dohme LLC | $30.07 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $28.86 | 2021 | |
| Ethicon US, LLC | $23.96 | 2021 | |
| Nestle Healthcare Nutrition INC. | $21.46 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $20.98 | 2024 | Rexulti |
| Sumitomo Pharma America, INC. | $19.78 | 2024 | Gemtesa |
| Biogen, INC. | $17.02 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.52 | 2022 | |
| Pfizer INC. | $14.61 | 2021 | |
| Pharmacosmos Therapeutics INC. | $14.00 | 2024 | Monoferric |
| Averitas Pharma INC. | $13.95 | 2024 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Soliz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.